WaveMan
WaveMan · Company
ATRC · Atricure, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ATRC AtriCure (ATRC) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001323885
Quote by TradingView
Congress · 1Form 144 · 7
Insider buyers, 180 days
0
Funds added, last quarter
155
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $498.8K priced

What the filings say about ATRC

Insiders, 180 days
-$3.5M net sold
8 sellers · 25% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2026-09-29
Planned sales (Form 144), 90 days
$1.9M
7 notices

AtriCure insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, AtriCure, Inc. insiders sold a net $3.5M of stock across 64 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Privitera Salvatore
Chief Technical Officer
SELL
2026-09-24 SECtraded 2026-09-23
4,519
$271.1K
+5.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (1 buy, 5 sales), the last on Sep 8, 2026.
  • The trade is 3.2% of the 142,745 shares held after it.
  • 2 other insiders sold within 30 days.
  • 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technical Officer Privitera Salvatore sold about $271.1K of ATRC under a 10b5-1 plan on Sep 23, 2026; 2 other insiders sold within 30 days and 155 funds added in the latest 13F quarter.
GROVES REGINA E
Director
SELL
2026-09-14 SECtraded 2026-09-11
5,313
$288.1K
+9.4%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Aug 6, 2025.
  • The trade is 15.4% of the 34,546 shares held after it.
  • 2 other insiders sold within 30 days.
  • 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GROVES REGINA E sold about $288.1K of ATRC on Sep 11, 2026; 2 other insiders sold within 30 days and 155 funds added in the latest 13F quarter.
Privitera Salvatore
Chief Technical Officer
SELL
2026-09-10 SECtraded 2026-09-08
3,657
$201.1K
+12.8%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on Sep 2, 2026.
  • The trade is 2.5% of the 147,264 shares held after it.
  • 2 other insiders sold within 30 days.
  • 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technical Officer Privitera Salvatore sold about $201.1K of ATRC under a 10b5-1 plan on Sep 8, 2026; 2 other insiders sold within 30 days and 155 funds added in the latest 13F quarter.
Privitera Salvatore
Chief Technical Officer
SELL
2026-09-04 SECtraded 2026-09-02
7,763
$407.6K
+14.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on May 30, 2024.
  • The trade is 5.1% of the 150,921 shares held after it.
  • 4 other insiders sold within 30 days.
  • 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technical Officer Privitera Salvatore sold about $407.6K of ATRC under a 10b5-1 plan on Sep 2, 2026; 4 other insiders sold within 30 days and 155 funds added in the latest 13F quarter.
Dahlquist Karl S.
Chief Legal Officer
SELL
2026-08-26 SECtraded 2026-08-24
9,370
$458.1K
+24.8%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Mar 18, 2024.
  • The trade is 10.7% of the 87,319 shares held after it.
  • 7 other insiders sold within 30 days.
  • 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Dahlquist Karl S. sold about $458.1K of ATRC on Aug 24, 2026; 7 other insiders sold within 30 days and 155 funds added in the latest 13F quarter.
64 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 59 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.5M over 180 days
-$1.9M over 90 days
below 73% of Medical Devices
Congress
1 member bought in the last year
the lowest in Medical Devices
Funds
155 funds bought in last quarter
more than 77% of Medical Devices
Revenue
+14.9% year over year
more than 59% of Medical Devices
Margin
-2.1% net margin
more than 66% of Medical Devices
Buybacks
no share repurchases reported
Short interest
10.0% of the float short (float per yahoo 2026-10-27) · 5.2 days to cover · settled 2026-10-15
more than 87% of Medical Devices
What changed in the last 30 days
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 13 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.

Watch ATRC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+64.5%12M
-31%+1%+33%+65%2025-102025-122026-022026-042026-062026-082026-10 2026-07-28 · WEHRWEIN SVEN sold $946.0K2026-08-24 · Dahlquist Karl S. sold $458.1K2026-09-02 · Privitera Salvatore sold $407.6K2026-09-11 · GROVES REGINA E sold $288.1K2026-09-23 · Privitera Salvatore sold $271.1K2026-07-29 · Noznesky Justin J sold $239.9K2026-07-28 · Doraiswamy Vinayak sold $233.3K2026-09-08 · Privitera Salvatore sold $201.1K2025-11-26 · Noznesky Justin J sold $192.6K2025-11-25 · WEHRWEIN SVEN sold $188.7K2025-11-24 · WEHRWEIN SVEN sold $187.8K2026-03-12 · Doraiswamy Vinayak sold $149.2K2026-05-15 · Doraiswamy Vinayak sold $140.7K2026-08-05 · Prange Karen sold $138.3K2026-08-05 · Yuen Maggie sold $134.5K2025-11-21 · Yuen Maggie sold $107.2K2026-05-20 · Prange Karen sold $86.0K2026-09-23 · SALVATORE PRIVITERA filed to sell $271.1K2026-09-11 · GROVES REGINA E filed to sell $285.1K2026-09-08 · SALVATORE PRIVITERA filed to sell $201.1K2026-09-02 · SALVATORE PRIVITERA filed to sell $407.6K2026-08-24 · KARL DAHLQUIST filed to sell $458.1K2026-08-05 · MAGGIE YUEN filed to sell $134.5K2026-08-05 · Prange Karen filed to sell $139.0K2026-07-29 · Noznesky Justin J filed to sell $239.9K2026-07-28 · SVEN WEHRWEIN filed to sell $964.4K2026-07-28 · VINAYAK DORAISWAMY filed to sell $233.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ATRC: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
4,474,548 sh
$125.2M
WELLINGTON MANAGEMENT GROUP LLP
3,495,603 sh
$97.8M
VANGUARD PORTFOLIO MANAGEMENT LLC
3,127,195 sh
$87.5M
Hood River Capital Management LLC
2,905,299 sh
$81.3M
ALLIANCEBERNSTEIN L.P.
2,768,365 sh
$79.0M

Congress trades in ATRC

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Gilbert Cisneros
Sold 2026-09-29 · disclosed 13 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2026-08-20 · disclosed 21 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2026-03-03 · disclosed 35 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2025-05-06 · disclosed 31 days later
$1,001 - $15,000
Josh Gottheimer
Bought 2024-07-19 · disclosed 27 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ATRC planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
SALVATORE PRIVITERA
Filed 2026-09-23
$271.1K
GROVES REGINA E
Filed 2026-09-11
$285.1K
SALVATORE PRIVITERA
Filed 2026-09-08
$201.1K
SALVATORE PRIVITERA
Filed 2026-09-02
$407.6K
KARL DAHLQUIST
Filed 2026-08-24
$458.1K

ATRC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
GRANDEUR PEAK US STALWARTS FUND
$461.3K position · as of 2026-07-31
2.7%
Osterweis Opportunity Fund
$9.9M position · as of 2026-06-30
2.6%
GRANDEUR PEAK GLOBAL CONTRARIAN FUND
$3.3M position · as of 2026-07-31
2.3%
GRANDEUR PEAK GLOBAL OPPORTUNITIES FUND
$7.9M position · as of 2026-07-31
2.3%
Advisors Capital Small/Mid Cap Fund
$2.9M position · as of 2026-06-30
2.3%
Nicholas Limited Edition, Inc.
$7.7M position · as of 2026-07-31
2.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
15 registered trials, 9 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
15
Not applicable
9 active
What changed recently
Inappropriate Sinus Tachycardia Registry
2026-10-08 · Completion moved 2027-01 → 2030-01
,
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$9.2M
$14.9M
$3.2M
-29%
-19%
2024
$11.1M
$6.8M
$3.0M
-45%
-34%
2023
$8.7M
$4.8M
$2.7M
-36%
-32%
2022
$8.3M
$248.2K
$2.3M
-20%
-32%
2021
$7.5M
$13.1M
$2.1M
+25%
-10%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.5M sold by insiders over 180 days, 155 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $1.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

ATRC financials

Revenue growth
+14.9%
XBRL, annual
Net margin
-2.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$569.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+1.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$53.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.13x
long-term 2026-06-30 plus current 2020-12-31 (66 months older than the period end); equity 2026-06-30
Cash flow to debt
0.96x
TTM operating cash flow over long-term 2026-06-30 plus current 2020-12-31 (66 months older than the period end)
Return on equity
+2.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+1.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+2.7%
operating income after a 12.8% effective tax rate, over long-term 2026-06-30 plus current 2020-12-31 (66 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+2.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
292.90x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$3.0B
market value at close 2026-10-27 on 2026-07-22 shares, plus long-term 2026-06-30 plus current 2020-12-31 (66 months older than the period end), minus cash 2026-06-30
FCF yield
+1.7%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122024-012023-12
Revenue$534.5M$465.3Mn/a$399.2M
Gross profit$400.8M$347.5Mn/a$300.4M
Operating income-$9.4M-$40.0Mn/a-$26.7M
Net income-$11.4M-$44.7Mn/a-$30.4M
EPS (diluted)-0.24-0.95n/a-0.66
Operating cash flow$57.3M$12.2Mn/a$4.5M
Cash$167.4M$122.7Mn/a$84.3M
Long-term debt$61.9M$61.9M$61.0M$60.6M
SEC XBRL, fiscal years, as known on 2026-10-28

ATRC Stock Sonar score 6/7 axes

Find similar shapesCompare

ATRC ranks highest on financial health (78th percentile) and growth (59th), and lowest on insider conviction (13th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
55
Inputs
  • Return on equity+2.2% · 70 pct, sector of 183
  • Return on assets+1.6% · 72 pct, sector of 214
  • Return on invested capital+2.7% · 6 pct, sector of 36
  • Return on capital employed+2.3% · 71 pct, sector of 188
Financial health
78
Inputs
  • Debt to equity0.13x · 65 pct, sector of 159
  • Cash flow to debt0.96x · 91 pct, sector of 150
Growth
59
Inputs
  • Revenue growth, YoY+14.9% · 59 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
13
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.7M · 27 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
46
Inputs
  • Funds adding, latest quarter155 · 77 pct, sector of 191
  • Congress net buyers, 365d0 · 40 pct, universe of 719
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$90K · 20 pct, sector of 50
Risk and compliance
45
Inputs
  • Short interest, % of float+9.9% · 21 pct, sector of 240
  • Recalls per $1B revenue, 3y3.74 per $1B · 25 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+3.8% · 88 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ATRC filings, in plain words

Are AtriCure insiders buying or selling ATRC?

In the 180 days to 2026-10-28, AtriCure insiders were net sellers, a net $3.5M across purchases and sales reported on Form 4, by 8 sellers.

Have members of Congress traded ATRC?

Yes. In the year to 2026-10-28, 1 House member disclosed buying ATRC and 1 House member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-09-29.

Are there planned insider sales of ATRC?

Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.9M of stock; the latest, by SALVATORE PRIVITERA, was filed 2026-09-23.

Read the full summary

In the 180 days to 2026-10-28, AtriCure insiders were net sellers of ATRC, a net $3.5M across purchases and sales reported on Form 4 by 8 sellers. 25% of the 12 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 1 member of Congress disclosed buying ATRC and 1 member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-09-29. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies